glp-1 drugs for parkinson's disease receptor agonists show promise in treating substance use disorders Can one drug do it

These findings highlight the potential clinical importance of achieving and maintaining weight loss after GLP-1-based treatment initiation. Meeting: European Congress on Obesity 2026 (ECO2026) Never miss a breakthrough: Join the SciTechDaily newsletter

Pfizer was the first major drug maker to reach a deal with Trump, slashing prices for some medicines by up to 85% on the TrumpRx site

I learned so much on all the ways to research effectively, thoroughly and truthfully

[DOI] [PubMed] [Google Scholar] 54.Baumgartner I, et al

Pediatric and adolescent obesity remains largely unaddressed by current approvals and clinical evidence

The program features expert presentations from regulatory scientists across multiple FDA offices, industry leaders from both innovator and generic companies, device manufacturers, and academic researchers, complemented by interactive Q&A panels and small working group discussions for in-person attendees at the end of each day